XLO

Business Context and Reporting Period

Xilio Therapeutics, Inc. (XLO) filed a Form 8-K on February 23, 2026, reporting the results of a special meeting of stockholders held on that date. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

Stockholders approved two key proposals at the special meeting:

• Proposal 1 (Reverse Stock Split): Approved an amendment to the restated certificate of incorporation to effect a reverse stock split. The ratio is set within a range of 1-for-2 to 1-for-30, with the exact ratio and timing to be determined by the Board of Directors without further stockholder approval.
• Proposal 2 (Adjournment): Approved the authority to adjourn the meeting to solicit additional proxies if necessary.

Voting Results for Proposal 1:

Voting Results for Proposal 2:

Guidance, Outlook, and Risks

The filing does not provide financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosure of the reverse stock split mechanism. The primary contingency noted is the Board's discretion to determine the final split ratio and implementation timing.

Investor Verification Checklist

• Verify the exact reverse stock split ratio and effective date once announced by the Board of Directors.
• Confirm the adjusted share count and par value following the implementation of the split.
• Review subsequent filings for any impact on the company's compliance with Nasdaq listing standards.
• Check for any related press releases detailing the strategic rationale for the split.